AstraZeneca
AZN
$75.03
Share price
5.38%
Change (1 day)
-1.03%
Change (1 year)
Categories
AstraZeneca (AZN) - Cash on Hand
Cash on Hand as of December 2023 : $5.86 B
According to AstraZeneca's latest financial reports the company has $5.86 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AstraZeneca - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $5.86 B | -6.13% |
| 2022-12-31 | $6.24 B | -2.42% |
| 2021-12-31 | $6.39 B | -19.94% |
| 2020-12-31 | $7.99 B | 28.55% |
| 2019-12-31 | $6.21 B | 11.14% |
| 2018-12-31 | $5.59 B | 22.84% |
| 2017-12-31 | $4.55 B | -21.63% |
| 2016-12-31 | $5.81 B | -13.82% |
| 2015-12-31 | $6.74 B | -4.23% |
| 2014-12-31 | $7.04 B | -28.84% |
| 2013-12-31 | $9.89 B | 20.32% |
| 2012-12-31 | $8.22 B | -27.08% |
| 2011-12-31 | $11.27 B | -4.64% |
| 2010-12-31 | $11.82 B | 3.71% |
| 2009-12-31 | $11.40 B | 159.67% |
| 2008-12-31 | $4.39 B | -26.3% |
| 2007-12-31 | $5.95 B | -22.46% |
| 2006-12-31 | $7.68 B | 54.33% |
| 2005-12-31 | $4.97 B | -5.43% |
| 2004-12-31 | $5.26 B | 33.26% |
| 2003-12-31 | $3.95 B | -15.72% |
| 2002-12-31 | $4.68 B | 22.63% |
| 2001-12-31 | $3.82 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 291.25% | 🇺🇸 USA |
 Novartis NVS | $13.96 B | 138.26% | 🇨🇭 Switzerland |
 Pfizer PFE | $12.69 B | 116.55% | 🇺🇸 USA |
 Abbott Laboratories ABT | $7.27 B | 24.22% | 🇺🇸 USA |
 Eli Lilly LLY | $2.92 B | -50.04% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 69.42% | 🇫🇷 France |
 Biogen BIIB | $1.04 B | -82.08% | 🇺🇸 USA |
 Merck MRK | $7.09 B | 21.04% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $12.28 B | 109.56% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $6.35 B | 8.44% | 🇬🇧 UK |